文献速递肿瘤 PET/CT放射性药物与辐射防护

使用正电子发射断层显像对FAP表达的无创成像:含糖肽的[18F]标记FAPI与[18F]FAPI-42的对比评估

Noninvasive imaging of FAP expression using positron emission tomography: A comparative evaluation of a [18F]-labeled glycopeptide-containing FAPI with [18F]FAPI-42.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2023-06-02

研究开发了含糖肽的[18F]标记FAPI示踪剂[18F]FAPT,在A549-FAP和U87MG荷瘤小鼠模型中与[18F]FAPI-42对比进行MicroPET及生物分布研究,并在5名健康志愿者和3例癌症患者中行[18F]FAPT PET/CT。结果显示[18F]FAPT与FAP特异性结合,亲水性更好、胆道系统摄取更低、肿瘤摄取更高且肿瘤滞留更长,除胰腺、甲状腺和唾液腺外正常组织摄取低,多数肿瘤可获得高靶/本底比。

要点

  • [18F]FAPT在临床前及临床研究中显示与FAP特异性结合,药代动力学性质良好。
  • 与[18F]FAPI-42相比,[18F]FAPT胆道系统摄取更低、肿瘤摄取更高、肿瘤滞留更长。
  • 健康志愿者和癌症患者中[18F]FAPT除胰腺、甲状腺和唾液腺外多数正常组织摄取低。

核心结论

  • [18F]FAPT是优于[18F]FAPI-42的胆道系统癌症PET显像示踪剂,可能为检查多数癌症的FAP表达提供工具,并获得高靶/本底比。

研究设计与样本

  • 研究手工和自动合成[18F]FAPT,用A549-FAP细胞体外检查其与FAP的竞争性结合、细胞内化和外流特征。
  • 在A549-FAP和U87MG荷瘤小鼠模型中进行[18F]FAPT动态MicroPET和生物分布研究,并与[18F]FAPI-42对比。
  • 5名健康志愿者和3例癌症患者接受[18F]FAPT PET/CT检查。

主要发现

  • 临床前和临床研究显示[18F]FAPT与FAP特异性结合,药代动力学性质良好,与[18F]FAPI-42相比亲水性更好、胆道系统摄取更低、肿瘤摄取更高且肿瘤滞留更长。
  • [18F]FAPT在健康志愿者和癌症患者中的生物分布显示,除胰腺、甲状腺和唾液腺外,大多数正常组织摄取低,有助于多数癌症获得高靶/本底比。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Research on fibroblast activating protein (FAP)-targeting inhibitor (FAPI) has become an important focus for cancer imaging and radiotherapy. Quinoline-based tracers [68 Ga]FAPI-04 and [18F]FAPI-42 have been widely used for positron emission tomography (PET) imaging of most tumors. However, there exist some limitations of these tracers with high uptake in biliary duct system and unstable uptake in pancreas, unsuitable for abdominal tumors PET imaging. Here we developed a [18F]-labeled glycopeptide-containing FAPI tracer (named [18F]FAPT) for PET imaging of FAP in cancers. METHODS: [18F]FAPT was synthesized manually and automatically. The competitive binding to FAP, cellular internalization, and efflux characteristics were examined in vitro using A549-FAP cells. Dynamic MicroPET and biodistribution studies of [18F]FAPT were then conducted in A549-FAP and U87MG xenograft tumor mouse models compared with [18F]FAPI-42. Five healthy volunteers and three patients with cancer underwent [18F]FAPT PET/CT. RESULTS: Preclinical and clinical studies showed specific binding of [18F]FAPT to FAP and favorable pharmacokinetic properties with better hydrophilicity, lower uptake in biliary duct system, higher tumor uptake and longer tumor retention compared with [18F]FAPI-42. The biodistribution of [18F]FAPT in healthy volunteers and patients with cancer displayed low uptake in most normal tissues except for pancreas, thyroid and salivary gland, which could contribute to high tumor-to-background ratios in most cancers. CONCLUSION: [18F]FAPT is better PET tracer than [18F]FAPI-42 for imaging of biliary duct system cancer, potentially providing a tool to examine FAP expression in most cancers with high tumor-to-background ratios.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Huang J, Fu L, Zhang X, et al. Noninvasive imaging of FAP expression using positron emission tomography: A comparative evaluation of a [18F]-labeled glycopeptide-containing FAPI with [18F]FAPI-42. Eur J Nucl Med Mol Imaging. 2023. PMID: 37266596. doi:10.1007/s00259-023-06282-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。